Mild cognitive impairment
Conditions
Interventions
Intervention Group:a2 skimmed milk powder
Control Group:Yili skimmed milk powder
Sponsors
The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
65 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 65-75 years; 2. Complaint of memory loss for more than 6 months; 3. Base on the Chinese version of Mini Mental State Examination (MMSE), cognitive ability score is lower than the standard cut-off value according to age and education levels: MMSE score <= 17 points if years of education is 0 year; <= 20 points if 6 years or less of education; <= 24 points if more than 6 years of education 4. Living and social functions are reduced: activities of daily living (ADL) score <= 18; 5. Not meeting the diagnostic criteria for dementia (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition), Alzheimer Disease (National Stroke Institute for Neuropathic Speech Disorders and Association for Alzheimer Disease and Related Disorders); no mental disorder, brain damage, or other physical disorders that can lead to cognitive impairment. 6. Agreed not to participate in another interventional clinical research study during the present study; 7. Signed informed consent
Exclusion criteria
Exclusion criteria: 1. Neurological examination showed focal signs of central nervous system disorder such as hemiplegia, dysesthesia, aphasia; history of cerebrovascular diseases (including hemorrhagic and ischemic types), internal brain trauma or fracture; 2. Asthmatic bronchitis, severe hypertension, angina and severe infection; 3. Mental disorders such as depression and anxiety; endocrine system diseases (such as hyperthyroidism, hypothyroidism, systemic lupus erythematosus, rheumatoid arthritis); 4. Newly diagnosed, progressing or advanced tumors; 5. Visual, reading, hearing impairment or language communication difficulties that significantly affect cognitive function tests; 6. History of alcohol dependence and abuse of psychoactive substances (e.g., antipsychotics, benzodiazepines, cholinesterase inhibitors, sedatives), or use of drugs that affect cognitive function; 7. Neurological diseases (e.g. Parkinson's disease, epilepsy); 8. Antibiotic treatment in previous 2 weeks; 9. Administered immunosuppressive drugs in the 4-weeks preceding screening; 10. Allergy to milk or dairy; 11. Diagnosed lactose intolerance; 12. Other diseases that investigators judged as unsuitable to participate the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subtle Cognitive Impairment Test (SCIT);glutathione; | — |
Secondary
| Measure | Time frame |
|---|---|
| calprotectin (S100A8/A9);myeloperoxidase;Short chain fatty acids, SCFAs;C-reactive protein, CRP;IL-1ß;IL-4;IL-8;TNF-a;IgE;IgG1;IgG2A;ß-tyrophin-7, BCM-7;galactose (qualitative test);Cyclophosphamide, CTX;osteocalcin;calcium;25-hydroxyvitamin D3, 25-OH-D3;grip;Montreal Cognitive Assessment Scale, MoCA;Auditory Verbal learning test, AVLT;Healthy Brain Ageing - Functional Assessment Questionnaire; | — |
Countries
China
Contacts
Public ContactKeming Zhang
The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Outcome results
None listed